Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer

Conditions:   Clear Cell Renal Cell Carcinoma;   Locally Advanced Unresectable Renal Cell Carcinoma;   Stage III Renal Cell Cancer AJCC v8 Intervention:   Drug: Cabozantinib Sponsors:   Emory University;   Exelixis Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

iro The practising clinician treating a patient with metastatic clear cell renal cell carcinoma (CCRCC) faces a difficult task of choosing the most appropriate therapeutic regimen in a rapidly developing field with recommendations derived from clinical trials. NCCN guidelines for kidney cancer initiated a major shift in risk categorization and now include emerging treatments in the neoadjuvant setting. Updates of European Association of Urology clinical guidelines also include immune checkpoint inhibition as the first-line treatment. Randomized trials have demonstrated a survival benefit for ipilimumab and nivolumab co...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Conditions:   Clear Cell Renal Cell Carcinoma;   Locally Advanced Unresectable Renal Cell Carcinoma;   Stage III Renal Cell Cancer AJCC v8 Intervention:   Drug: Cabozantinib Sponsors:   Emory University;   Exelixis Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
We describe common side effects of this treatment, and advise how they are best prevented and managed.
Source: European Urology - Category: Urology & Nephrology Source Type: research
Conclusions: This meta-analysis demonstrated that CD44 overexpression might be an unfavorable prognostic factor for CRC patients and could be used to predict poor differentiation, lymph node metastasis and distant metastasis. Introduction Although therapies for colorectal cancer (CRC) has improved in recent years, colorectal cancer is still the third most common cause of cancer related death worldwide (1). Metastasis are observed in 25% of patients at initial diagnosis and approximately 50% of patients will develop metastasis (2). Presently, the outcome prediction and the therapy schedule determination of CRC patie...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Li Liu, Jiajing Lin and Hongying He* Department of Obstetrics and Gynecology, Liuzhou Worker’s Hospital, Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, China Background and Objective: Endometrial cancer (EC) is a common gynecological malignancy worldwide. Despite advances in the development of strategies for treating EC, prognosis of the disease remains unsatisfactory, especially for advanced EC. The aim of this study was to identify novel genes that can be used as potential biomarkers for identifying the prognosis of EC and to construct a novel risk stratification using these genes. Me...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
This study aimed to investigate whether combining anti-PD-L1 Atezolizumab with BEV may have a synergistic effect and enhance the efficacy of both treatments in cisplatin resistant epithelial ovarian cancer (CREOC). We retrospectively analyzed 124 epithelial ovarian cancer (EOC) patients from Gynecologic Oncology Department of Tianjin Cancer Hospital between January 2013 and June 2018, who all were diagnosed with cisplatin resistance due to progressing
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Seon Ah Lim1†, Jungwon Kim1†, Seunghyun Jeon1†, Min Hwa Shin1, Joonha Kwon1, Tae-Jin Kim1, Kyungtaek Im1, Youngmin Han2, Wooil Kwon2, Sun-Whe Kim2, Cassian Yee3, Seong-Jin Kim4*, Jin-Young Jang2* and Kyung-Mi Lee1,3,5* 1Department of Biochemistry and Molecular Biology, Korea University College of Medicine, Seoul, South Korea 2Department of Surgery and Cancer Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea 3Department of Melanoma Medical Oncology and Immunology, MD Anderson Cancer Center, Houston, TX, United States 4Prec...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
ConclusionsPreoperative immunotherapy with nivolumab and ipilimumab for locally advanced clear cell renal cancer resulted in a complete response of an extensive vena cava tumor thrombus, which enabled curative-intent resection of a non-responding primary tumor. If validated in larger cohorts, preoperative immunotherapy for locally advanced renal cell carcinoma may ultimately impact surgical planning and long-term prognosis.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Kidney Cancer | Neoadjuvant Therapy | Renal Cell Carcinoma | Research | Urology & Nephrology